Industry experts note that AI's hype in biotech echoes the dot-com era, with a transition toward AI applications that deliver tangible value rather than overpromising.
AI is transforming biopharma with a shift towards decentralized and human-centric clinical models to reduce burdens on coordinators and improve data quality and patient experience.
BioCurie, a company led by CEO Irene Rombel, applies AI combined with mechanistic modeling to optimize and scale the manufacturing of advanced genomic medicines, offering transparency favored by regulatory bodies like the FDA.